Ultimovacs ASA

OB:ULTI Stock Report

Market Cap: NOK 85.5m

Ultimovacs Management

Management criteria checks 3/4

Ultimovacs' CEO is Carlos de Sousa, appointed in Jun 2020, has a tenure of 4.58 years. total yearly compensation is NOK6.50M, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth NOK64.75K. The average tenure of the management team and the board of directors is 6 years and 10 years respectively.

Key information

Carlos de Sousa

Chief executive officer

NOK 6.5m

Total compensation

CEO salary percentage74.5%
CEO tenure4.6yrs
CEO ownership0.08%
Management average tenure6yrs
Board average tenure10yrs

Recent management updates

Recent updates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Feb 21
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Oct 26
Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Oct 05
Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

May 19
Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27
Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

CEO Compensation Analysis

How has Carlos de Sousa's remuneration changed compared to Ultimovacs's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-NOK 149m

Jun 30 2024n/an/a

-NOK 179m

Mar 31 2024n/an/a

-NOK 178m

Dec 31 2023NOK 7mNOK 5m

-NOK 189m

Sep 30 2023n/an/a

-NOK 204m

Jun 30 2023n/an/a

-NOK 186m

Mar 31 2023n/an/a

-NOK 165m

Dec 31 2022NOK 8mNOK 5m

-NOK 168m

Sep 30 2022n/an/a

-NOK 148m

Jun 30 2022n/an/a

-NOK 153m

Mar 31 2022n/an/a

-NOK 168m

Dec 31 2021n/an/a

-NOK 165m

Sep 30 2021n/an/a

-NOK 138m

Jun 30 2021n/an/a

-NOK 126m

Mar 31 2021n/an/a

-NOK 124m

Dec 31 2020NOK 5mNOK 3m

-NOK 121m

Compensation vs Market: Carlos's total compensation ($USD576.84K) is above average for companies of similar size in the Norwegian market ($USD283.45K).

Compensation vs Earnings: Carlos's compensation has been consistent with company performance over the past year.

CEO

Carlos de Sousa (66 yo)

4.6yrs

Tenure

NOK 6,504,000

Compensation

Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Carlos de Sousa
Chief Executive Officer4.6yrsNOK 6.50m0.076%
NOK 64.7k
Hans Eid
Chief Financial Officer9.2yrsNOK 4.41m0.17%
NOK 142.1k
Audun Tornes
Chief Technology Officer3.9yrsNOK 2.92mno data
Jens Egil Bjorheim
Chief Medical Officer8.6yrsNOK 4.29mno data
Oivind Foss
Head of Clinical Operations7.4yrsNOK 2.71mno data
Orla Mc Callion
Head of Regulatory Affairs & QA3.3yrsNOK 2.37mno data
Torill Trones
Head of Officeno datano datano data

6.0yrs

Average Tenure

Experienced Management: ULTI's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonas Einarsson
Independent Chairman14yrsNOK 450.00k0.015%
NOK 13.2k
Kari Gronas
Independent Director6yrsNOK 250.00k0.019%
NOK 16.5k
Henrik Schussler
Director10yrsNOK 250.00kno data

10.0yrs

Average Tenure

61yo

Average Age

Experienced Board: ULTI's board of directors are seasoned and experienced ( 10 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 04:32
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ultimovacs ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Geir HolomDNB Markets
Christian BinderRedeye